Altered vesicular dopamine storage in Parkinson's disease: a premature demise.
about
A biochemical and functional protein complex involving dopamine synthesis and transport into synaptic vesicles.Dopamine and paraquat enhance α-synuclein-induced alterations in membrane conductanceThe Drosophila vesicular monoamine transporter reduces pesticide-induced loss of dopaminergic neurons.Nonmotor symptoms of Parkinson's disease revealed in an animal model with reduced monoamine storage capacityAlpha-synuclein disrupted dopamine homeostasis leads to dopaminergic neuron degeneration in Caenorhabditis elegans.Antidepressant-like effect of tetrahydroisoquinoline amines in the animal model of depressive disorder induced by repeated administration of a low dose of reserpine: behavioral and neurochemical studies in the rat.Reduced vesicular storage of catecholamines causes progressive degeneration in the locus ceruleus.Increased vesicular monoamine transporter enhances dopamine release and opposes Parkinson disease-related neurodegeneration in vivoRole of oxidative stress in Parkinson's disease.Dysautonomia in Parkinson diseaseCritical aspects of clinical trial design for novel cell and gene therapies.Increased Vesicular Monoamine Transporter 2 (VMAT2; Slc18a2) Protects against Methamphetamine ToxicityIndustrial toxicants and Parkinson's disease.The hypoxia imaging agent CuII(atsm) is neuroprotective and improves motor and cognitive functions in multiple animal models of Parkinson's disease.Selective damage to dopaminergic transporters following exposure to the brominated flame retardant, HBCDDExposure to the polybrominated diphenyl ether mixture DE-71 damages the nigrostriatal dopamine system: role of dopamine handling in neurotoxicity.alpha-Synuclein: a therapeutic target for Parkinson's disease?Interplay between cytosolic dopamine, calcium, and alpha-synuclein causes selective death of substantia nigra neuronsGeraniol ameliorates the motor behavior and neurotrophic factors inadequacy in MPTP-induced mice model of Parkinson's disease.Understanding the molecular basis of Parkinson's disease, identification of biomarkers and routes to therapy.Membrane transporters as mediators of synaptic dopamine dynamics: implications for disease.Protein reactivity of 3,4-dihydroxyphenylacetaldehyde, a toxic dopamine metabolite, is dependent on both the aldehyde and the catechol.Formation of covalent di-tyrosine dimers in recombinant α-synuclein.A fluorescent-based assay for live cell, spatially resolved assessment of vesicular monoamine transporter 2-mediated neurotransmitter transport.Alteration to Dopaminergic Synapses Following Exposure to Perfluorooctane Sulfonate (PFOS), in Vitro and in Vivo.Impairment in the mesohippocampal dopamine circuit following exposure to the brominated flame retardant, HBCDD.Immunochemical localization of vesicular monoamine transporter 2 (VMAT2) in mouse brain.Quinoprotein adducts accumulate in the substantia nigra of aged rats and correlate with dopamine-induced toxicity in SH-SY5Y cells.Tyrosine Hydroxylase, Vesicular Monoamine Transporter and Dopamine Transporter mRNA Expression in Nigrostriatal Tissue of Rats with Pedunculopontine Neurotoxic Lesion.VPS35 mutation in Japanese patients with typical Parkinson's disease.Behavioral and neurochemical effects induced by reserpine in mice.The antioxidant and neurochemical activity of Apium graveolens L. and its ameliorative effect on MPTP-induced Parkinson-like symptoms in mice.Dopamine induces mitochondrial depolarization without activating PINK1-mediated mitophagy.Dopaminergic mediation in the brain aging and neurodegenerative diseases: a role of senescent cells.Graphene Oxide Modified Electrodes for Dopamine Sensing
P2860
Q27863413-B7BD81C7-F8AB-4115-8502-F051A34E75A8Q28392011-907ED6C8-2137-4E54-8623-2F058CA73FC2Q30430534-857F3695-D436-4343-9915-1441F9A27806Q33617472-FD172503-E7FA-41F8-9900-4D1722C9BB5EQ33670439-D2BF9CA6-7DBD-4E47-90C5-060A5B068CC0Q33671819-CDEA69D7-12E4-4D91-8EC2-9354DB6D4AF9Q33724885-B5A29540-33A8-4180-AF02-42D31D562B2CQ33919548-131437EA-54EE-49EB-9664-1207DE93CCDDQ34339252-B3F5614C-E71E-4D48-962E-71D15100DC63Q34463831-9AC38BEC-57AD-48C2-8C17-D209D60E8575Q35664438-92E345A5-8F7A-4F6A-8175-E6E63D4604EEQ35810975-67A8F96C-60A2-495A-9FD0-872CB3602E65Q35822952-CDE465B0-0CB7-4EF9-A0DF-4C0E92ACAA15Q35894167-D21DADE2-C488-43FA-B520-665074BBF6D9Q36366275-4EFAE29D-F027-4E88-8744-39152ADCEC84Q36693263-0003698A-EC5D-4030-93F2-B0B651A682DAQ37070916-74036B5A-D038-450D-ADD8-D3E35E9D7841Q37180671-B044649A-A40E-494F-86FE-5DC07FFB9F75Q37298364-A596B574-92D4-4233-9E41-9479823C32F5Q37775037-C4D76DD5-1450-4D01-93B7-D8ED23B4D325Q38926644-79B3DCA4-5E19-40CC-A305-B88D9F3F0354Q41786059-05B287CB-73C6-4A73-95C2-CD4F39B3E6C6Q41786303-A22C5C22-83FE-479B-8B28-3720668DF2ABQ42321665-56DE371C-3F7E-408C-853F-2948F1D17F3EQ42705599-EA3751E1-421E-4E08-B2A8-2CB23150A55FQ48302719-D00201A2-840F-45F3-A306-1505E371C890Q48433008-C5958A62-BB41-41DF-A5BD-AE2562E68E6CQ49016618-6E110D79-FB63-4FCA-8DF0-724B4654D1B0Q49490658-097ACC97-7ED5-4F9E-9E30-0FDF42541CB6Q50254001-B234549D-C87F-4AF0-8394-DC4C8B5F9209Q52147414-C58B6CC9-6CA1-4DE4-AE69-11B4CC8E3E0DQ52646464-D9B8B033-F019-4E85-8102-1492193D2584Q52892369-C4FC90FC-5538-434C-BA79-CE0575F27E4FQ55077179-83D55B58-4479-4349-9C10-DBA9DF6C109DQ59146782-D5B8C74D-DEDC-473D-BFD3-22660C4F6380
P2860
Altered vesicular dopamine storage in Parkinson's disease: a premature demise.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 09 May 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Altered vesicular dopamine storage in Parkinson's disease: a premature demise.
@en
Altered vesicular dopamine storage in Parkinson's disease: a premature demise.
@nl
type
label
Altered vesicular dopamine storage in Parkinson's disease: a premature demise.
@en
Altered vesicular dopamine storage in Parkinson's disease: a premature demise.
@nl
prefLabel
Altered vesicular dopamine storage in Parkinson's disease: a premature demise.
@en
Altered vesicular dopamine storage in Parkinson's disease: a premature demise.
@nl
P2093
P1476
Altered vesicular dopamine storage in Parkinson's disease: a premature demise.
@en
P2093
Gary W Miller
Piers C Emson
Rebecca E Colebrooke
W Michael Caudle
P304
P356
10.1016/J.TINS.2008.02.010
P577
2008-05-09T00:00:00Z